Spots Global Cancer Trial Database for Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
Official Title: A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours
Study ID: NCT00973076
Interventions
Study Description
Brief Summary: The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Tokyo, , Japan
Contact Details
Name: Ian Smith
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Tomohide Tamura
Affiliation: National Cancer Center Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
